Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Colorectal cancer

IL-15

Patient studies suggest IL-15 could be useful for treating colorectal cancer. In a cohort of patients with colorectal cancer, carriers of an IL-15 deletion had lower IL-15 expression and showed lower levels of B and T cell proliferation in the tumor microenvironment than patients without the deletion. Carriers of the IL-15 deletion also showed increased risk of tumor recurrence and decreased survival. Next steps include developing mouse models to evaluate the therapeutic use of IL-15 alone and in combination with checkpoint inhibitors.
Altor BioScience Corp. has ALT-803, an IL-15-mutant agonist complexed to an Fc fusion protein of IL-15 receptor a-chain (IL-15RA), in Phase I testing to treat melanoma and preclinical development for other cancers.
Cytune Pharma S.A.S. has CYP0150, a fusion protein of IL-15 and IL-15RA, in preclinical development for cancer (see Leveling cancer with IL-15 page 7).

SciBX 7(16); doi:10.1038/scibx.2014.456
Published online April 24, 2014

Patent application filed covering gene signature for cancer prognosis and tumor classification that includes IL-15; available for licensing and partnering

Mlecnik, B. et al. Sci. Transl. Med.; published online March 19, 2014;
doi:10.1126/scitranslmed.3007240
Contact: Jérôme Galon, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France
e-mail:

jerome.galon@crc.jussieu.fr